# Neuromuscular Drugs Ref — NM Pharmacology

> NM Pharmacology (iPhone/iPad app by ATIF ELNIL.)

- Source: https://appshunter.io/ios/app/neuromuscular-drugs-ref/id6761312986 (this page in markdown: same URL + `.md`)
- Developer: [ATIF ELNIL](https://appshunter.io/developer/1886307011)
- Category: Medical, Education
- Price: $12.99
- Age rating: 17+
- Requires: iOS 26.4 · 15 MB
- Languages: American English
- Released: 2026-04-01
- Data updated: 2026-05-21
- User reviews in markdown: https://appshunter.io/ios/app/neuromuscular-drugs-ref/id6761312986/reviews.md

## What is Neuromuscular Drugs Ref?

DESCRIPTION:
IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions.
 
Neuromuscular Drugs Reference is a comprehensive evidence-based drug reference for neuromuscular pharmacology. Built for neurologists, anaesthetists, intensivists, and allied health professionals managing patients with neuromuscular disease.
 
MYASTHENIA GRAVIS DRUGS
- Acetylcholinesterase inhibitors: pyridostigmine full dosing protocol, neostigmine IV use, propantheline for side effects, cholinergic crisis recognition (SLUDGE)
- Corticosteroids: prednisolone slow titration protocol, initial worsening warning (30-50%), bone and gastric protection, IV methylprednisolone for ICI toxicity
- Steroid-sparing agents: azathioprine with TPMT testing requirement, mycophenolate mofetil, ciclosporin — full monitoring table with pre-treatment tests, ongoing tests, and onset timelines
- Biologics: rituximab (anti-CD20, best in anti-MuSK MG), eculizumab (NICE TA6022 approved, meningococcal vaccination protocol), efgartigimod/Vyvgart (NICE 2022, IV and SC formulations), rozanolixizumab/Rystiggo (MHRA 2023), zilucoplan/Zilbrysq (MHRA 2023, daily SC)
 
NEUROMUSCULAR BLOCKERS
- Suxamethonium: RSI dosing, hyperkalaemia mechanism in denervated muscle, full contraindication list, malignant hyperthermia trigger
- Non-depolarising agents
- Reversal agents: sugammadex dosing (2/4/16mg/kg), why it is preferred over neostigmine in MG, neostigmine plus glycopyrrolate protocol, train-of-four monitoring principles
- Special populations: GBS, MG, renal failure, hepatic failure, burns, malignant hyperthermia, LEMS — drug choice table
 
GBS AND CIDP DRUGS
- IVIg: full dosing protocol for GBS and MG crisis, CIDP acute and maintenance dosing, start rates, brand information (Privigen, Kiovig, Flebogamma), IgA check requirement, pre-medication, AKI avoidance, side effects management table
- Plasma exchange: 5-session protocol, replacement fluid choice, contraindications, complications table (hypotension, hypocalcaemia, coagulopathy)
- CIDP maintenance: subcutaneous immunoglobulin (SCIg) with PATH trial evidence, Hizentra dosing, prednisolone protocol, PREDICT trial summary
- Supportive drugs

LAMBERT-EATON DRUGS
- Amifampridine (Firdapse)
- Pyridostigmine adjunct dosing in LEMS
- Malignancy screen protocol
- IVIg and plasma exchange in acute LEMS
 
BOTULINUM TOXIN
- All four UK licensed preparations
- Six therapeutic indications with doses
- Complications table:
 
STATIN MYOPATHY
- Full SAMS spectrum table
- Risk factors
- Rhabdomyolysis 6-step emergency protocol
- SANAM (statin-associated necrotising autoimmune myopathy)
- Statin re-introduction strategy
 
ICU NEUROMUSCULAR DRUGS
- NMBA indications, TOF monitoring principles, limiting duration to 24-48h
- Sedation agents:
- Opioids
- ICUAW prevention drug strategies
 
DRUG INTERACTIONS
- Comprehensive table of drugs worsening MG
- Drugs prolonging NMJ blocker duration
- Safe antiemetics in MG
- Antiemetics to AVOID in MG
 
INTERACTIVE FEATURES
- Drug search: 30+ searchable entries across all sections — tap result to navigate directly to the relevant section
- Quiz mode: 10 clinical pharmacology questions with detailed explanations covering all 9 sections
- My Notes: personal clinical notes saved during the session
- Font size adjustment: A- / A+ text scaling for bedside use
- 25+ tappable references including NICE TA6022, REGAIN trial, ADAPT trial, SID-GBS 2023, PATH trial, ACURASYS trial, PREEMPT trials, anti-HMGCR myopathy literature, BNF, MHRA drug safety updates
 
DISCLAIMER
This app is intended for use by qualified healthcare professionals only as a clinical decision-support and educational reference tool. It does not replace individual clinical assessment, local prescribing protocols or official prescribing information. Always consult the current BNF before prescribing.

## Chart rankings

- #198 in Top Paid · Medical (US App Store)


## Version history (last 1 release)

### 1.0 — 2026-04-01

No release notes.

## More apps by ATIF ELNIL

- [Antiseizure Medications](https://appshunter.io/ios/app/antiseizure-medications/id6760823031)
- [NIHSS Calculator](https://appshunter.io/ios/app/nihss-calculator/id6760891744)
- [HyperRef Clinical](https://appshunter.io/ios/app/hyperref-clinical/id6760921930)
- [PD Drug Reference](https://appshunter.io/ios/app/pd-drug-reference/id6760972673)
- [MS DMT Reference](https://appshunter.io/ios/app/ms-dmt-reference/id6761038062)
- [ElectroBalance Pro](https://appshunter.io/ios/app/electrobalance-pro/id6761238034)

All apps by ATIF ELNIL: https://appshunter.io/developer/1886307011

---

*Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-05-21.*